Navigation Links
New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
Date:9/8/2008

Results add to body of clinical evidence demonstrating the efficacy and

safety of synthetic mesh slings for treatment of stress urinary

incontinence in women.

SOMERVILLE, N.J., Sept. 8 /PRNewswire/ -- A new study published in the August issue of International Urogynecology Journal analyzes data of an 11-year follow up study on the safety and effectiveness of tension-free vaginal tape (TVT) as a treatment for stress urinary incontinence (SUI) in women. Researchers followed women treated with GYNECARE TVT(TM) Retropubic System Tension-free Support for Incontinence and found that after 11 years, 90% were objectively cured and 97% considered themselves subjectively cured or improved. This study represents the most extensive follow up for modern mid-urethral sling operations to date.

The three-center prospective observational cohort study led by Professor Carl G. Nilsson, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland, reports on 90 women suffering from urinary stress incontinence who were treated with GYNECARE TVT. Pre-operative assessment included a 24-hour pad test, a stress test, physical examination and a visual analog scale for assessing how bothersome the condition was to each patient. Of the original cohort, 69 women were available for post-operative follow-up 11.5 years after surgery. These women were evaluated using a stress test, a pad test, the patient's overall impression of the cure and a questionnaire administered to assess the patient's quality of life. More than 11 years after surgery, 97% of women assessed subjectively considered themselves cured or improved and researchers determined that 90% of patients were objectively cured based on 24-hour pad tests and stress tests.

"Our results substantiate the evidence showing that the TVT procedure is a safe, effective solution that offers excellent long-term cure rates for women suffering with SUI," said Prof
'/>"/>

SOURCE ETHICON Women's Health & Urology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
2. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
3. Study Suggests a Possible Way to Offset Chemobrain Memory Loss
4. Cytopia Commences Second Phase II Study in Brain Cancer
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. CDC Misses Target With Flawed MMR/Autism Study
8. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
9. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
10. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
11. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2US Oncology Reports Second Quarter Operating Results 53858 1US Oncology Reports Second Quarter Operating Results 53858 2US Oncology Reports Second Quarter Operating Results 53858 3US Oncology Reports Second Quarter Operating Results 53858 4US Oncology Reports Second Quarter Operating Results 53858 5US Oncology Reports Second Quarter Operating Results 53858 6US Oncology Reports Second Quarter Operating Results 53858 7US Oncology Reports Second Quarter Operating Results 53858 8US Oncology Reports Second Quarter Operating Results 53858 9US Oncology Reports Second Quarter Operating Results 53858 10US Oncology Reports Second Quarter Operating Results 53858 11US Oncology Reports Second Quarter Operating Results 53858 12US Oncology Reports Second Quarter Operating Results 53858 13US Oncology Reports Second Quarter Operating Results 53858 14US Oncology Reports Second Quarter Operating Results 53858 15US Oncology Reports Second Quarter Operating Results 53858 16US Oncology Reports Second Quarter Operating Results 53858 17US Oncology Reports Second Quarter Operating Results 53858 18US Oncology Reports Second Quarter Operating Results 53858 19US Oncology Reports Second Quarter Operating Results 53858 20US Oncology Reports Second Quarter Operating Results 53858 21US Oncology Reports Second Quarter Operating Results 53858 22US Oncology Reports Second Quarter Operating Results 53858 23US Oncology Reports Second Quarter Operating Results 53858 24US Oncology Reports Second Quarter Operating Results 53858 25Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 1Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 2Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 3BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 1BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 2BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 3
...o, a division of Merck KGaA, Darmstadt, Germany, t... develop and commercialize Ambrx,s ARX424 preclini...e sclerosis. ARX424 was created by Ambrx through ...ation technology, ReCODE(TM). , , This second col...vious agreement announced in 2007 to develop ARX20...
...ceuticals, Inc. (Nasdaq: MAPP ) announced today ...nit Dose Budesonide (UDB) for the potential,treatm...d that the clinical,trial did not meet its co-prim...es from baseline in nighttime and daytime composit..., when compared with placebo. Median,nebulization...
Other Medicine Technology:Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 2Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 3MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...CFS) has been associated with altered amounts of s...oencephalograph (EEG) activity and impaired sleep... journal SLEEP finds that CFS is also associated w...Roseanna Armitage, PhD, and colleagues at the Univ...
... not pose a risk of cancer; a Danish study conduct... has shown. Danish medical records were a... cancer, or brain cancer among the utility workers...bstantial evidence linking exposure to electro mag...
... have died in a hospital here in the month of Apri...ed from his post for not informing the state gove...s, however, put the number of infant deaths at the...sts conducted at the microbiology department of th...
...eed lift one out of depression. But its potential ...ognized . Now the U.S. Food and Drug Admin...tidepressant medications update the existing black...ring initial treatment, generally the first one to...
...Dakota is now infusing roasted sunflower seeds w...energy drinks , to provide players and other peopl... The product, which has been under developmen...e, lysine and ginseng are added. The 3.5-ounc...
...rchers, diabetes is fast becoming a common reason ...he Reproductive Medicine Research Group at Queen's... semen samples of 57 men who were diagnosed with D...such samples it was seen that diabetes brought abo...
Other Medicine News:Health News:Government Expels Superintendent for Not Informing Newborn Deaths 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:Fertility Rates Felled By Diabetes 2
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: